Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arzoxifene versus raloxifene in postmenopausal women with osteoporosis
2006-001987-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of arzoxifene and raloxifene in osteoporosis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at 12 months. Started Jul 2006; status: completed.
02
Drugs
arzoxifeneraloxifene
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2006-001987-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001987-22.